CLBR001 is a Chimeric antigen receptor T (CAR-T) cell product that
comprises the patient’s T cells and a novel “switchable” chimeric
antigen receptor (sCAR-T). SWI019 is an Antibody Fab-based biologic,
called the “switch”, which targets the B cell antigen CD19. CLBR001
+ SWI019 are being developed by Calibr in a Phase I first in patient
clinical trial for patients with B cell malignancies.
AbbVie and Calibr will also work together to develop novel switchable T-cell therapies directed to various tumor targets identified by AbbVie. AbbVie also has option to license certain existing Calibr cell therapy programs under development for hematological and solid cancers, including Calibr's lead program.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted, Approved)|